Background and Purpose-Statins improve infarct volume and neurological outcome in animal stroke models. We investigated the relationship between statin therapy and ischemic stroke outcome in the North Dublin Population Stroke Study. Methods-A population-based prospective cohort study was performed using rigorous ascertainment methods. Prestroke and acute (Յ72 hours) poststroke medications were recorded. Modified Rankin score and fatality were assessed at 7, 28, and 90 days and 1 year. Results-Of 448 ischemic stroke patients, statins were prescribed before stroke onset in 30.1% (134/445) and were begun acutely (Յ72 hours) in an additional 42.5% (189/445). On logistic regression analysis, adjusting for age, prestroke disability (modified Rankin scale), NIHSS score, hypertension, and aspirin, new poststroke statin therapy was independently associated with improved early and late survival (compared with statin untreated patients: OR for death, 0.12; CI, 0.03-0.54 at 7 days; OR, 0.19; CI, 0.07-0.48 at 90 days; OR, 0.26; CI, 0.12-0.55 at 1 year; PՅ0.006 for all). Similar findings were observed for statin therapy before stroke onset (adjusted OR for death compared with statin-untreated-patients, 0.04; CI, 0.00 -0.33; Pϭ0.003 at 7 days; OR, 0.23; CI, 0.09 -0.58; Pϭ0.002 at 90 days; OR, 0.48; CI, 0.23-1.01; Pϭ0.05 at 1 year). Conclusions-Statin therapy at stroke onset and newly begun statins were associated with improved early and late outcomes, supporting data from experimental studies. Randomized trials of statin therapy for treatment of acute stroke are needed. (Stroke. 2011;42:1021-1029.)
I n randomized trials, 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) prevent stroke in survivors of first stroke and in other patients at high risk with vascular disease. 1, 2 Statins also may improve outcomes after stroke. Infarct volume is reduced by pretreatment or early introduction of statin therapy in experimental acute stroke models. [3] [4] [5] [6] [7] [8] [9] In rodents, statin pretreatment has been associated with reduced neurological disability after focal brain ischemia. 4 -6 Rats treated with atorvastatin 24 hours after focal ischemia had enhanced neurological function, angiogenesis, synaptogenesis, and neuronal progenitor cell migration in the periinfarct region compared to controls. 10 Experimental data suggest that statins have vasodilatory, antithrombotic, antiinflammatory, antioxidant, and neuroprotective effects, which may mediate these benefits. 5-7,9 -11 Although providing some support for a neuroprotective role of statins in acute stroke, findings from clinical studies have been inconsistent. Whereas some observational studies have reported reduced mortality or improved functional outcomes in patients treated with statins before stroke onset, these benefits were not observed in other studies. [12] [13] [14] [15] [16] [17] [18] [19] [20] The findings from randomized controlled trials again have been variable. In the MISTICS trial, neurological outcome was improved at 3 days in patients randomized to simvastatin, but no functional improvement was observed at 90 days. 21 In the SPARCL trial, there was a reduction in stroke frequency across the range of stroke severity, with a trend toward improved functional outcome in patients with a recurrence while using statin therapy. 22 A trial of 89 patients randomized to statin withdrawal or continued statin treatment found an association between statin cessation and poorer outcomes in the early poststroke period. 23 Some randomized trials also have raised safety concerns, with nonsignificant trends toward increased mortality, infection, 21 or recurrence 20 observed in patients treated with statins after stroke. Interpretation of these studies is difficult. Many observational studies have been restricted to hospital-admitted patients, which may lead to bias. Others have been limited by retrospective design, short follow-up periods, or insufficient statistical power for analysis of confounding variables. No adequately powered clinical trials have yet investigated whether statin treatment begun acutely after stroke onset is associated with improved outcome.
Randomized trials of early statin therapy after stroke are expensive and time-consuming to conduct. Prospective population-based studies with early and late follow-up may clarify the relationship of statin therapy with outcome and may better-inform clinical trial design. We hypothesized that statin treatment, before stroke onset and begun acutely after ischemic stroke, would be associated with greater survival and improved functional outcome. We investigated this hypothesis in the North Dublin Population Stroke Study cohort.
Subjects and Methods

Case Ascertainment
The North Dublin Population Stroke Study is a population-based prospective cohort study of stroke and TIA in North Dublin city (census-defined population of 294 529). 24 After a pilot study to refine ascertainment procedures, individuals with stroke and TIA occurring between December 1, 2005 and November 30, 2006 were ascertained using multiple overlapping hospital and community sources. Both "hot" and "cold" pursuits were undertaken according to recommended rigorous criteria for stroke incidence studies. 25 Ascertainment was continued for another 3 months to identify eligible patients within the study period who delayed seeking medical attention.
Patients were recruited within 72 hours of the qualifying event. Hospital ascertainment took place in 4 acute and 9 non-acute hospitals. Sources included outpatient clinics, emergency department referrals, and daily reviews of hospital admissions and consultation requests to neurology, elderly medicine, neurosurgery, vascular surgery, and eye services. Brain and vascular imaging study requests were reviewed twice weekly. Community ascertainment involved North Dublin general practitioners (94% participation), nursing residential homes (95% participation), death certificate data, and city coroner records. A daily minor stroke/TIA clinic facilitated rapid referral of community-based patients. Patients with suspected stroke who died were ascertained by review of pathology, coroner, and death certification records.
All suspected cases were assessed by a trained study physician, with in-person assessment for diagnostic queries, suspected TIA or recurrent stroke. The World Health Organization definition of stroke was used. 26 Prestroke function was rated using the modified Rankin scale (mRS) within 72 hours of stroke onset by interview performed by trained study staff with patient or a family member. Acute poststroke function (mRS) and stroke severity (Ͻ72 hours) using NIHSS scores were measured. Coronary artery disease, hypertension, hyperlipidemia, and diabetes mellitus were recorded as present when a patient had a previous physician-confirmed diagnosis of these conditions. Atrial fibrillation was coded as present if a physician-confirmed diagnosis of preexisting or new atrial fibrillation (persistent or paroxysmal) existed and was confirmed on ECG or Holter monitor at the time of the acute stroke. Patients were classified as current smokers if they endorsed a clinical history of any tobacco smoking within 1 week of stroke onset. Prestroke statin status was established by history from the patient, medical notes, and, when necessary, by liaison with the patient's general practitioner. Acute poststroke statin status was taken from the patient's medical notes and in-hospital prescription record, when applicable.
Follow-up assessments including mRS were performed at 7, 28, and 90 days and 1 year by trained study staff unaware of medication status. Follow-up was performed in-person or by telephone interview, supplemented by medical record review when required.
Inclusion Criteria
For this analysis, inclusion criteria were: (1) new ischemic stroke, verified by imaging or autopsy; (2) residence within North Dublin city; and (3) age 18 years or older. We excluded patients with TIA, hemorrhagic stroke, and those identified via coroner's records for whom further clinical information was unavailable.
Ethical Approval
Ethics approval was obtained from all participating institutions and the Irish College of General Practitioners. Informed consent was obtained from patients or next-of-kin.
Statistical Analyses
Three-way comparisons of clinical variables were performed using the 2 test for categorical variables, ANOVA was used for parametric analysis, and Friedman's test was used for nonparametric analysis of continuous variables. Post hoc 2-way comparisons were performed by 2 and t tests, with Bonferroni correction for multiple comparisons. Life table analysis and Kaplan-Meier curves were used for actuarial assessment of survival at defined time intervals after stroke onset. Because the relative hazard for death was not constant over time, proportional hazards regression analysis was not considered valid.
Univariate analyses were performed to identify any association between outcomes (fatality and functional outcome) and clinical and demographic variables. Similar analysis was also performed for treatment strategies that have been associated previously with stroke outcomes, including intensive care, stroke unit care, thrombolysis, statin, aspirin, and antihypertensive treatment. Logistic regression was performed to determine likelihood of survival at each time interval, with OR Ͻ1.0 favoring survival and OR Ͼ1.0 indicating greater likelihood of death. Logistic regression was also performed for analysis of good functional outcome (mRS, 0 -2) and statin dose-response analyses.
An a priori strategy was specified for inclusion of variables associated with outcome at PϽ0.1 in multivariable logistic regression models. When statistical evidence of collinearity was present between candidate predictor variables, these were not included in the final model if inclusion did not change the model fit (as assessed by pseudo R 2 ) or findings. Model-building was then performed using forward stepwise logistic regression.
To allow comparison between statin-untreated patients and those receiving treatment before stroke onset or new treatment in the acute poststroke period (Ͻ72 hours), statin treatment was categorized as a trichotomous variable as prestroke, new acute poststroke, and statinuntreated. To investigate for the possibility of treatment selection bias favoring new statin-treated patients after stroke, we conducted a secondary analysis in which patients receiving statin therapy before stroke were compared to those not using prestroke statins. For this analysis, the comparison group included both patients prescribed statins de novo after stroke and statin-untreated patients. We conducted an exploratory analysis to investigate for a dose-response relationship between statin dose and outcome in atorvastatin-treated patients. We avoided assumptions of linearity for atorvastatin doses by defining categorical variables as 10 to 20 mg and 40 to 80 mg, with statin-untreated patients as the reference group. Analyses were performed using Stata (version 9). Significance tests were 2-sided.
Results
Patient Characteristics
Overall, 567 new stroke events occurred during the study period. Of these, 57 (10.1%) had intracerebral hemorrhage, 28 (4.94%) had subarachnoid hemorrhage, 22 (3.9%) were coroner-ascertained, and 12 (2.1%) had unknown pathology and were excluded. Four hundred forty-eight patients were included with confirmed ischemic stroke (446 by imaging: 418/446 CT [93.7%], 233/446 MRI [52.2%], 2 patients at autopsy; Figure 1 ).
Prestroke medication data were available for 445 (99.3%), and acute poststroke medication data (Յ72 hours) were available for 431 patients (96.2%). One hundred thirty-four (30.1%) were using statin therapy before stroke onset. Of these, statins were continued after stroke in 117 (87.3%) and discontinued in 12 patients (Figure 1 ). Another 189 patients (43.9%) had new statin therapy begun within 72 hours of stroke onset. Overall, 306 (71.0%) patients were treated with statins acutely after stroke onset.
The most commonly prescribed prestroke statins were atorvastatin (70.2%; 94/134 patients) and pravastatin (24.6%; 33/134). Atorvastatin dose ranged from 10 to 80 mg, with 65 patients (69.1%) prescribed 20 mg or less daily. Pravastatin dose range was 10 to 40 mg, with 25 (75.8%) prescribed 20 mg or less. Within 72 hours of stroke onset, 266 patients were using atorvastatin (86.9% of poststroke statins), with 133 (50%) prescribed 10 to 20 mg daily. Pravastatin was prescribed acutely in a further 36 patients (11.8% of poststroke statins) at doses of 10 or 20 mg in 25 patients. Patients on statin treatment prior to stroke onset had lower acute poststroke total cholesterol and low-density lipoprotein levels (Pϭ0.0002 compared with no pre-stroke statin therapy; Table 1 ).
Patients using statin therapy before stroke onset had greater frequencies of vascular risk factors, including coronary artery disease, hyperlipidemia, and hypertension (PϽ0.05 for all; Table 1 ). They also had higher frequencies of characteristics previously associated with poor stroke outcome, including atrial fibrillation (Pϭ0.01), diabetes mellitus (PϽ0.001), and previous stroke (PϽ0.001; Table 1 ). Compared to statinuntreated patients, those begun on new statin treatment within 72 hours were younger (Pϭ0.04), with less frequent atrial fibrillation (Pϭ0.03) and higher rates of smoking (Pϭ0.004; Table 1) .
Sixty-seven patients (15.0%) were admitted to a stroke unit and 29 (6.5%) were admitted to an intensive care unit. No differences in thrombolysis, stroke unit, or intensive care treatment were observed between patients receiving statin therapy and those not. Patients treated with statins acutely after stroke were more likely to receive aspirin (PϽ0.001; Table 1 ). However, there were no differences in antihyper- tensive treatment between statin-treated and statin-untreated patients.
Early Stroke Severity
Compared to statin-untreated patients, those commenced on statins acutely after stroke had lower NIHSS (Pϭ0.04) and mRS scores within 72 hours (Pϭ0.007; Table 1) . No difference in early stroke severity was observed between patients using prestroke statins and statin-untreated patients. On univariate analysis of the relationship between statin treatment and poststroke fatality, OR and 95% CI were consistently Ͻ1.0, indicating a statin-associated survival benefit.
Early and 1-Year Survival
Compared to statin-untreated patients, new statin therapy (Ͻ72 hours after stroke) was associated with improved 7-day survival (OR, 0.09; CI, 0.03-0.32; PϽ0.0001), as was statin treatment before stroke onset (OR, 0.08; CI, 0.02-0.38; Pϭ0.001; Table 2; Table I available online at http:// stroke.ahajournals.org). Improved 7-day survival was also associated with acute aspirin therapy (OR, 0.22; Pϭ0.001), whereas poorer prestroke functional status (mRS; Pϭ 0.02), higher NIHSS score (PϽ0.0001), hypertension (Pϭ0.007), and age (Pϭ0.08) were associated with lower likelihood of early survival. Similar findings were observed at 90 days and 1 year ( Table 2; Table I ).
On logistic regression analysis, adjusting for age, prestroke mRS score, NIHSS score, hypertension, acute aspirin, prestroke statin, and new acute poststroke statin treatment, new poststroke statin therapy was independently associated with survival at 7 days (OR, 0.12; CI, 0.03-0.54; Pϭ0.006) and 90 days ( Figure 2 ). Discontinuation of statin therapy acutely after stroke (12 patients) was not associated with increased fatality.
In a secondary analysis, we compared patients using prestroke statin therapy to those not using statins before stroke (including statin-untreated after stroke and those prescribed statins de novo after stroke; Table II 
001).
When patients receiving any acute poststroke statins (continued or new treatment) were compared with statin-untreated patients, statin use was associated with good functional outcome (mRS, 0 -2) at 7, 28, and 90 days and 1 year. The OR for good functional outcome associated with acute statin therapy at 7 days was 2.1 (CI, 1.34 -3.34; Pϭ0.001) and at 1 year was 1.93 (CI, 1.25-2.97; Pϭ0.003). Other factors associated with good outcome were younger age, male gender, lower prestroke mRS score, lower NIHSS score, absence of previous stroke and atrial fibrillation, and acute aspirin treatment (all PϽ0.05). After adjusting for age, gender, prestroke mRS score, NIHSS score, and acute aspirin treatment, acute statin therapy after stroke was independently associated with good functional outcome at 7 days (OR, 2.12; CI, 1.06 -4.24; Pϭ0.03), with a trend at 90 days (OR, 1.81; CI, 0.94 -3.49; Pϭ0.08). Lower age, prestroke mRS score, and NIHSS score were independently associated with good outcome at all time points (PՅ0.001 for all). When patients using prestroke statins were compared to those not (including statin-untreated and new statin-treated after stroke), no association between prestroke statin and functional outcome was observed.
Statin Dose, Survival, and Functional Outcome
In a post hoc analysis, we examined the relationship between statin dose and outcome. Because most patients were treated with atorvastatin (86.9% 266/306 acutely after stroke), and to facilitate interpretation of our findings, analysis was restricted to atorvastatin-treated patients categorized as statin-untreated, 10 mg to 20 mg, and Ն40 mg.
For each category change in acute poststroke atorvastatin, improved likelihood of survival was observed at 7, 28, and 90 days and 1 year (PϽ0.001 at all time intervals). After adjusting for age, prestroke mRS score, NIHSS score, hypertension, and acute aspirin therapy, change in atorvastatin dose category was associated with survival, with reductions in the odds of death for each change in dose category at all time intervals (OR, 0.18; CI, 0.62-0.49; Pϭ0.001 at 7 days; OR, 0.36; CI, 0.21-0.63; PϽ0.001 at 90 days; OR, 0.59; CI, 0.40 -0.89; Pϭ0.01 at 1 year).
When stratified by the timing of atorvastatin therapy, increasing dose of atorvastatin before stroke onset was independently associated with survival at 7 days (adjusted OR, 0.11; CI, 0.01-1.02; Pϭ0.05), with a statistical trend at 28 days (adjusted OR, 0.38; CI, 0.13-1.11; Pϭ0.08). Increasing dose of atorvastatin begun within 72 hours of stroke onset was associated with improved likelihood of survival at all time intervals (adjusted OR, 0.22; CI, 0.07-0.71; Pϭ0.01 at 7 days; adjusted OR, 0.46; CI, 0.27-0.79; Pϭ0.005 at 1 year).
After adjusting for age, gender, prestroke mRS score, NIHSS score, and acute aspirin treatment, change in dose category of poststroke atorvastatin was also associated with good outcome at 7 days (OR, 1.6; CI, 1.07-2.36; Pϭ0.02) and 90 days (OR, 1.47; CI, 1.00 -2.15; Pϭ0.05). When the dose-response analyses were repeated after excluding atorvastatin-untreated patients (ie, dose category 0 mg), the association between atorvastatin dose and outcome was no longer observed. 
Discussion
To our knowledge, we describe the largest prospective study to date of acute treatment and pretreatment with statins and their relationship with survival and functional outcome at early and late time intervals after stroke. The main finding was a consistent association between new acute statin treatment and improved survival, which was maintained at 1 year and persisted after adjusting for other known major determinants of stroke outcome. We further observed some evidence suggesting a dose-response relationship between atorvastatin treatment acutely after stroke and survival at early and late time intervals. New acute statin treatment was also associated with good functional recovery at early time points and 1 year, with statistical trends favoring early benefit after adjusting for other prognostic factors. These findings were further supported by the analysis of pretreatment with statins and stroke outcome. After adjusting for other known determinants of stroke outcome, statin pretreatment was associated with improved survival at 1 week, with benefit maintained at 1 year. These findings were observed despite the fact that patients pretreated with statins had higher frequencies of conditions associated with worse stroke outcome, including atrial fibrillation, diabetes mellitus, and previous stroke. Statin treatment before stroke was also independently associated with good functional outcome at 90 days.
In an exploratory analysis, we also observed a relationship between increasing atorvastatin dose category and improved likelihood of survival and good functional outcome. However, when we excluded atorvastatin-untreated patients, this relationship was no longer apparent. Several factors may account for this finding. It is possible that the dose-response was primarily driven by worse outcomes in atorvastatinuntreated patients. Alternatively, a threshold-dependent rather than dose-dependent relationship for atorvastatin exposure in the peri-stroke period may predominate, such that any statin treatment may be of greater importance than a change in the statin dose. Third, it is possible that an underlying dose-response was not detected because of reduced statistical power when statin-untreated patients were excluded. For now, we caution that these findings should be considered hypothesis-generating and require further investigation in clinical studies.
Several studies have reported improved clinical outcomes after stroke associated with statin treatment before stroke onset. [12] [13] [14] [15] [16] [17] [18] However, to our knowledge no large studies exist of the relationship between acute poststroke statin therapy and outcome. The potential effects of acute statin treatment after stroke are particularly relevant, because most patients experiencing stroke will not be using statin therapy before stroke onset, and clinical trials of acute statin therapy would likely begin treatment in this time window to maximize anticipated benefits. Two preliminary studies of 30 and 33 statin-treated patients did not report significant major adverse effects associated with early poststroke statin therapy. 21, 27 Other clinical data suggesting statinrelated benefits exist. Statin therapy started within 4 weeks of stroke has been associated with improved functional status, 17 whereas early statin withdrawal has been associated with early neurological deterioration and death or dependency at 3 months. 23 Although providing valuable information, earlier studies often have been limited by retrospective design, small numbers of statin-treated patients, brief follow-up duration, and unavailability of information on functional outcome.
Statins have neuroprotective and microvascular benefits in animal stroke models. In mice, pretreatment with high-dose simvastatin and mevastatin caused upregulation of endothelial nitric oxide synthase, enhanced cerebral blood flow, reduced infarct volume, and improved neurological function. 5, 6 In rat embolic stroke models, oral administration of lower doses (1 mg/kg and 3 mg/kg) of atorvastatin within 24 hours enhanced vascular endothelial growth factor expression, neovascularization, proliferation of neural progenitor cells, synaptogenesis, and neurological function. 10 These findings suggest that early statin administration, at doses similar to those used in clinical practice, may augment cerebral repair after ischemic injury via increased neurogenesis and angiogenesis.
The pleiotropic effects suggested in experimental models may contribute to the benefits observed with statin therapy in our study. The greatest benefit of statin pretreatment on survival was observed at 1 week compared to later time intervals, which may indicate that an underlying neuroprotective mechanism partially explains our findings. However, the benefit observed with new statin treatment begun soon after stroke onset may indicate that neuro-restorative mechanisms also contribute. Because statins may modify other factors influencing stroke outcome, including recurrence, coronary events, and infection, 2, 28 it is possible that mechanisms other than neuroprotection or cerebral repair may partially explain our findings. However, we did not observe a significant relationship between statin use and recurrent stroke.
Strengths of our study include its large size, high rates of statin treatment in prestroke and acute poststroke phases, prolonged follow-up, and availability of outcome data for 95% of patients. Our population-based design utilized rigorous methods consistent with recommendations for high-quality epidemiological stroke studies 25 and minimized selection bias, which may complicate hospital-based studies.
However, we acknowledge limitations of our study. We cannot exclude the possibility that biased statin prescribing favoring less impaired patients (confounding by indication) may partially contribute to our findings. Although it is possible that unmeasured factors related to statin prescribing patterns may partially account for our findings, the association of statin therapy with improved outcome persisted after adjusting for other important determinants of prognosis, including age, stroke severity, prestroke functional status, and aspirin treatment. No evidence was seen indicating that statin-treated patients had greater intensity of stroke unit or intensive care treatment, or of prescribing of nonaspirin antithrombotic or antihypertensive medications. Although the magnitude of benefit was attenuated, an early benefit was also observed when we compared prestroke statin recipients with those not receiving prestroke statin therapy. Stroke severity will not have influenced prestroke statin prescribing, increasing the likelihood that an underlying neuroprotective effect, and not treatment selection bias, accounts for this finding.
Other limitations also exist. The agent and dose of prescribed statin varied, which may influence underlying effects on stroke outcome. This is inevitable in observational studies of "real-world" practice and was mitigated by the use of atorvastatin in 87% of patients after stroke. Information on cause of death was not available, precluding analysis of statin use and vascular versus nonvascular deaths.
Conclusions
Randomized trials will be required to determine whether statin therapy improves outcome after ischemic stroke. Whereas trials of statin pretreatment may not be practical, our data support clinical trials investigating early initiation of statin treatment after stroke, which are more feasible. Although some data are available, 20, 27 additional safety and efficacy studies should be prioritized. Two such trials, STARS07 29 and NeuStart II, 30 are ongoing and will provide valuable information in the near future. 
